Alpha Cognition Stock Price, News & Analysis

Alpha Cognition (NASDAQ: ACOG) has announced strategic appointments to strengthen its commercial and medical teams ahead of the ZUNVEYL launch, its treatment for mild to moderate Alzheimer's disease, planned for Q1 2025. The company has appointed:

- Jen Pesa as VP of Commercial, bringing 25 years of pharmaceutical experience and 12 successful product launches
- Jack Kelly as Head of Market Access, with 30+ years in pharmaceutical industry
- Rommel Fernandez as VP of Corporate Strategy and Operations, with 17 years of experience in pharma and biotech
- Kurt Grady as VP of Medical Affairs, bringing 30 years of healthcare experience

These appointments aim to build the commercial infrastructure necessary for ZUNVEYL's nationwide pharmacy launch, with particular focus on the long-term care (LTC) segment.

Alpha Cognition (ACOG) has entered into a $44 million exclusive licensing agreement with China Medical System Holdings for ZUNVEYL (benzgalantamine) in Asia (excluding Japan), Australia, and New Zealand. The agreement includes $6 million in upfront payments plus development and commercial milestone payments, along with royalties on net sales.

ZUNVEYL, an FDA-approved oral treatment for mild-to-moderate Alzheimer's disease, will be developed, manufactured, and commercialized by CMS in the licensed territories. The target market includes an estimated 50 million people with Alzheimer's disease in the region. Alpha Cognition maintains its plans for a U.S. launch in Q1 2025.

Alpha Cognition (ACOG) has announced an investor update call scheduled for January 28th, 2025, at 4pm EST to present its commercial launch strategy for ZUNVEYL (benzgalantamine), their FDA-approved treatment for mild-to-moderate Alzheimer's disease. The presentation will focus on addressing the $2 billion U.S. long-term care market.

ZUNVEYL is notably only the second oral Alzheimer's treatment approved in over a decade. The call will feature presentations from the company's leadership team, including CEO Michael McFadden and COO/CCO Lauren D'Angelo, alongside key thought leaders Dr. Hany Mohamed and Cathy Parker, who bring extensive experience in long-term care settings.

The presentation will cover market positioning, launch strategy, and long-term growth objectives for the Q1 2025 commercial launch.

Alpha Cognition (Nasdaq: ACOG) announced that underwriters have partially exercised their over-allotment option to purchase an additional 488,506 common shares at US$5.75 per share, generating US$2.8 million in additional gross proceeds. Following this exercise, the company's total offering reached 9,184,159 shares, raising approximately US$52.8 million in gross proceeds before deducting expenses.

The company's shares began trading on The Nasdaq Capital Market on November 12, 2024, under ticker ACOG. Proceeds will fund ZUNVEYL™ commercialization for Alzheimer's Disease, pipeline product development, commercial CMC activities, and working capital. Titan Partners Group is serving as Sole Bookrunner for the offering.

Alpha Cognition (NASDAQ: ACOG) has announced its voluntary delisting from the Canadian Securities Exchange (CSE), effective at the close of trading on December 17, 2024. The company's common shares will continue to trade exclusively on the Nasdaq Capital Market under the symbol 'ACOG'. This decision comes in connection with the company's existing Nasdaq listing.

Alpha Cognition (ACOG) announced positive interim preclinical data for ALPHA-1062 in treating mild traumatic brain injury (mTBI), specifically focusing on blast trauma injuries relevant to military personnel. The study, conducted in collaboration with the Seattle Institute of Biomedical and Clinical Research and supported by the US Department of Defense, showed promising results in a rodent model.

The interim data revealed that ALPHA-1062 administration following three consecutive days of blast-induced mTBI reduced neuroinflammation markers and neuropathology. High doses demonstrated reduced myeloid cell activation across multiple brain regions and decreased midbrain astrogliosis one month after blast. Final study results, including neuropathology and neurobehavioral data analysis, are expected in Q2/2025.

Alpha Cognition (NASDAQ: ACOG) reported Q3 2024 financial results and corporate updates. The company received FDA approval for ZUNVEYL, an Alzheimer's disease treatment, with commercial launch planned for Q1 2025. Key highlights include: $4.5M raised in bridge financing, successful manufacturing stability tests extending ZUNVEYL's shelf life to 24 months, and NASDAQ listing preparation. Financial results show Q3 2024 R&D expenses of $1.0M (down from $1.4M in Q3 2023), G&A expenses of $1.2M (up from $0.8M), and a net loss of $1.9M ($0.31 per share). Cash position stands at $3.7M as of September 30, 2024.

Alpha Cognition (ACOG) has announced the pricing of its upsized public offering of 8,695,653 common shares at $5.75 per share, raising approximately $50 million in gross proceeds. The company has granted underwriters a 30-day option to purchase up to 1,184,592 additional shares. The offering is expected to close on November 13, 2024. ACOG will begin trading on Nasdaq on November 12, 2024. Proceeds will fund the commercialization of ZUNVEYL for Alzheimer's Disease, pipeline development, CMC activities, and working capital.

Alpha Cognition Inc. (OTCQB: ACOG) (CSE: ACOG) reported financial results for Q2 and H1 2024, highlighting the FDA approval of ZUNVEYL for mild-to-moderate Alzheimer's disease. The company's R&D expenses decreased to $0.9 million in Q2 and $1.9 million in H1 2024, down from $1.3 million and $2.4 million in the same periods of 2023. G&A expenses increased to $1.2 million in Q2 and $4.4 million in H1 2024, up from $0.6 million and $1.3 million in 2023. The Q2 2024 net loss was $2.1 million ($0.01 per share), and H1 2024 net loss was $7.1 million ($0.05 per share). Cash and cash equivalents stood at $1.0 million as of June 30, 2024.